Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study
Sign Up to like & getrecommendations! Published in 2018 at "European Respiratory Journal"
DOI: 10.1183/13993003.01467-2017
Abstract: ALK rearrangement and EGFR/KRAS mutations constitute the primary biomarkers tested to provide targeted or nontargeted therapies in advanced nonsmall cell lung cancer (NSCLC) patients. Our objective was to assess the cost-effectiveness of biomarker testing for… read more here.
Keywords: biomarker; cost effectiveness; biomarker testing; advanced nonsmall ... See more keywords
Apatinib for advanced nonsmall-cell lung cancer: A retrospective case series analysis
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Cancer Research and Therapeutics"
DOI: 10.4103/jcrt.jcrt_258_17
Abstract: Objectives: Apatinib, a tyrosine kinase inhibitor which selectively inhibits vascular endothelial growth factor receptor-2, has been shown to be beneficial to patients with a variety of cancers, including advanced nonsmall-cell lung cancer (NSCLC). Thus, this… read more here.
Keywords: apatinib; cell lung; nonsmall cell; lung cancer ... See more keywords